Clinical Trials
41 trialsNCT06694454 2026-05-27
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06843447 2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05431270 2026-05-19
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT06904378 2026-05-19
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1/2 Recruiting
NCT06498648 2026-05-13
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06802835 2026-05-11
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT03652428 2026-05-06
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
University of Maryland, Baltimore
Phase 1/2 Recruiting
NCT07563738 2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2 Recruiting
NCT06483555 2026-04-23
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07020221 2026-04-22
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
NCT05786924 2026-04-21
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Phase 1/2 Recruiting
NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04577014 2026-04-14
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT07223047 2026-04-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06445062 2026-04-01
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06704191 2026-03-30
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting
NCT07392541 2026-03-23
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Tongji Hospital
Phase 1/2 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06821503 2026-03-10
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT07049055 2026-02-27
Carolyn-USA
Engeneic Pty Limited
Phase 1/2 Recruiting
NCT05300282 2026-01-28
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Phase 1/2 Recruiting
NCT06548412 2026-01-20
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07296341 2026-01-14
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04495296 2025-12-19
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT07229586 2025-12-19
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07259590 2025-12-02
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Recruiting
NCT05482893 2025-11-04
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT07124936 2025-08-15
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06460298 2025-08-12
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
ProDa BioTech, LLC
Phase 1/2 Recruiting
NCT06026657 2025-07-08
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05141149 2025-06-04
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
Prestige Biopharma Limited
Phase 1/2 Recruiting
NCT06956716 2025-05-04
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University
Phase 1/2 Recruiting
NCT05827796 2025-04-30
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT03579836 2025-03-10
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
BeyondBio Inc.
Phase 1/2 Recruiting
NCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT06202261 2024-03-12
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT05525247 2023-09-21
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Selecxine
Phase 1/2 Recruiting
NCT05981001 2023-08-08
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting